KRAS mutations affect about 40% of colorectal cancers, and G12D is the most common. Genmab will conduct the study; Incyte ...
Disease control was 62.2% vs. 36.8%; crossover-adjusted overall survival was not statistically significant (HR 0.85; p=0.53).
The 56% response rate came from 25 patients with CEA-high tumors; BeOne intends to advance both lung programs toward ...
For that subgroup, response rate was 59% with the triplet vs. 33% with alpelisib plus fulvestrant; median response duration ...
Simard joined XBiotech in 2012 and contributed to clinical-trial design; Shivaswamy became chief scientific officer in 2017, ...
Study patients had high-grade serous, platinum-resistant ovarian cancer and a median of four prior lines of therapy. Call ...
The Phase 1 cohort included 33 women, 67% previously treated with PARP inhibitors; Lilly is studying Sofe-M in three global ...
PRAME-high melanoma: 12.5-month median response duration; 91% alive at one year. First data on IMA402 with IMA401 in lung cancer are expected in 2027.
The analysis included 295 people and found reductions in all four urinary markers, adding evidence FILSPARI may affect ...
At week 12, 60% of patients without prior advanced therapy failure had an endoscopic response, versus 15% on placebo; ...
Among 459 participants, more with blood in urine saw it resolve on sefaxersen than placebo; blinded follow-up will measure ...
Share-transfer books are expected to close Nov. 5. Elme plans to move remaining assets to a trust; the trustee sets the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results